BeiGene Ltd. ADR | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,902.90
18,473.50
57,066.60
118,978.00
93,615.60
5,282,764.10
Depreciation, Depletion & Amortization
1,593.80
1,550.90
1,544.00
1,905.20
4,605.60
77,544.70
Other Funds
2,633.00
9,793.60
13,442.70
13,647.60
50,277.00
1,219,404.50
Funds from Operations
3,676.10
7,129.00
42,079.90
104,191.70
44,597.80
4,157,841.20
Changes in Working Capital
7,753.70
1,531.00
2,261.60
14,858.20
57,393.10
134,915.50
Net Operating Cash Flow
4,077.60
8,660.00
39,818.30
89,333.60
12,795.30
4,292,756.70
Capital Expenditures
264.30
651.40
5,310.70
23,454.90
58,927.30
Sale of Fixed Assets & Businesses
14.00
-
1.00
4.00
34,559.90
Purchase/Sale of Investments
-
30,424.60
53,559.70
197,952.40
318,584.30
Net Investing Cash Flow
250.30
33,509.50
58,869.40
221,403.30
342,951.70
Issuance/Reduction of Debt, Net
482.50
16,599.90
5,849.40
12,023.80
133,207.50
Net Financing Cash Flow
482.50
51,961.10
103,141.00
380,138.40
477,443.60
Net Change in Cash
3,303.70
9,933.00
3,968.50
69,505.40
152,604.10
Free Cash Flow
3,813.30
9,311.50
45,129.00
112,788.50
33,736.10
Deferred Taxes & Investment Tax Credit
-
-
-
766.50
5,864.80
172,026.30
Net Assets from Acquisitions
-
2,433.50
-
-
-
Change in Capital Stock
-
35,361.30
97,291.60
368,114.60
344,236.10
Exchange Rate Effect
41.00
141.40
484.70
103.80
5,317.00

About BeiGene

View Profile
Address
Zhongguancun Life Science Park
Beijing Beijing 102206
China
Employees -
Website http://www.beigene.com
Updated 07/08/2019
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V.